Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Eyenovia, Inc.
  6. News
  7. Summary
    EYEN   US30234E1047

EYENOVIA, INC.

(EYEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eyenovia to Participate in Two Upcoming Investor Conferences

07/07/2021 | 04:01pm EDT

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.

Details of the Ladenburg presentation are below:

Date:Wednesday, July 14, 2021
Time:9:00AM Eastern Time
Webcast:https://wsw.com/webcast/ladenburg7/eyen/2421499

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(603) 489-5964


Primary Logo


ę GlobeNewswire 2021
All news about EYENOVIA, INC.
09/17EYENOVIA : Arctic Vision Expand Licence Deal to Include Another Eye Drug
MT
09/17Arctic Vision Announces Addition of Novel Mydriatic Drug MydcombiÖ to Eyenovia Commerci..
CI
09/15EYENOVIA : Material Definitive Agreement (Form 8-K)
PU
09/15EYENOVIA, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
09/15Eyenovia, Inc. Enters into Amendment to Certain License Agreement with Arctic Vision (H..
CI
08/12EYENOVIA : Management's Discussion and Analysis of Financial Condition and Results of Oper..
AQ
08/11EYENOVIA : Announced positive topline data from its Phase 3 VISION-1 study evaluating Micr..
PU
08/11EYENOVIA, INC. : Results of Operations and Financial Condition, Other Events, Financial St..
AQ
08/11Eyenovia, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/11Eyenovia Reports Second Quarter 2021 Financial Results
GL
More news
Analyst Recommendations on EYENOVIA, INC.
More recommendations
Financials (USD)
Sales 2021 3,49 M - -
Net income 2021 -22,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -8,19x
Yield 2021 -
Capitalization 171 M 171 M -
Capi. / Sales 2021 48,9x
Capi. / Sales 2022 17,0x
Nbr of Employees 33
Free-Float 63,8%
Chart EYENOVIA, INC.
Duration : Period :
Eyenovia, Inc. Technical Analysis Chart | EYEN | US30234E1047 | MarketScreener
Technical analysis trends EYENOVIA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,58 $
Average target price 15,67 $
Spread / Average Target 138%
EPS Revisions
Managers and Directors
Sean Ianchulev President, CEO, Director & Chief Medical Officer
John P. Gandolfo Chief Financial Officer & Secretary
Fredric N. Eshelman Chairman
Luke Clauson VP-Engineering, Research & Development
Jennifer Clasby VP-Clinical Operations & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
EYENOVIA, INC.8.58%171
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.17.25%241 985
ELI LILLY AND COMPANY44.37%220 979